Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - atazanavir sulfate - capsule - 150mg

Μάλτα - Αγγλικά - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - atazanavir sulfate - hard capsule - atazanavir sulfate 200 mg - antivirals for systemic use

Μάλτα - Αγγλικά - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - atazanavir sulfate - hard capsule - atazanavir sulfate 300 mg - antivirals for systemic use

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

rowex ltd - atazanavir sulfate - capsule, hard - 200 milligram(s) - atazanavir

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

rowex ltd - atazanavir sulfate - capsule, hard - 300 milligram(s) - atazanavir

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - atazanavir sulfate - capsule, hard - 300 milligram(s) - atazanavir

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - atazanavir sulfate, quantity: 341.7 mg (equivalent: atazanavir, qty 300 mg) - capsule - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; titanium dioxide; brilliant blue fcf; purified water; iron oxide yellow; iron oxide red; erythrosine; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - atazanavir sulfate, quantity: 227.8 mg (equivalent: atazanavir, qty 200 mg) - capsule - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; titanium dioxide; brilliant blue fcf; purified water; erythrosine; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: -   atazanavir capsules are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus. -   use of atazanavir/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . atazanavir is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [see warnings and precautions (5.2)] . - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concentrations of the interacting drugs are asso